0001209191-18-047483.txt : 20180817 0001209191-18-047483.hdr.sgml : 20180817 20180817172642 ACCESSION NUMBER: 0001209191-18-047483 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180815 FILED AS OF DATE: 20180817 DATE AS OF CHANGE: 20180817 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lombardo Ilise CENTRAL INDEX KEY: 0001750158 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37418 FILM NUMBER: 181026616 MAIL ADDRESS: STREET 1: C/O AXOVANT SCIENCES, INC. STREET 2: 11 TIMES SQUARE, 33RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Axovant Sciences Ltd. CENTRAL INDEX KEY: 0001636050 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D0 FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 20-22 BEDFORD ROW CITY: LONDON STATE: X0 ZIP: WC1R 4JS BUSINESS PHONE: 441-295-5950 MAIL ADDRESS: STREET 1: 20-22 BEDFORD ROW CITY: LONDON STATE: X0 ZIP: WC1R 4JS FORMER COMPANY: FORMER CONFORMED NAME: Axovant Sciences, Inc. DATE OF NAME CHANGE: 20150324 FORMER COMPANY: FORMER CONFORMED NAME: Roivant Neurosciences Ltd. DATE OF NAME CHANGE: 20150309 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-08-15 0 0001636050 Axovant Sciences Ltd. AXON 0001750158 Lombardo Ilise C/O AXOVANT SCIENCES, INC. 11 TIMES SQUARE, 33RD FLOOR NEW YORK NY 10036 0 1 0 0 Chief Medical Officer Stock Option (Right to Buy) 2.02 2018-08-15 4 A 0 100000 0.00 A 2028-08-14 Common Shares 100000 100000 D One-third of the option will vest at such time as the Issuer's stock price is equal to $6.06; one-third of the option will vest at such time as the Issuer's stock price is equal to $10.10; and one-third of the option will vest at such time as the Issuer's stock price is equal to $14.14, in each case subject to the Reporting Person providing continuous service to the Issuer on each such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. /s/ Alison Haggerty, Attorney-in-Fact 2018-08-17